Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Hawaii Biotech identified new botulinum neurotoxin inhibitors

Jan. 12, 2021

Viralym-M enters phase III for virus-associated hemorrhagic cystitis

Jan. 12, 2021

rVSV-deltaG-spike vaccine protects hamsters against SARS-CoV-2 challenge

Jan. 12, 2021

Tocilizumab to be used in U.K. for ICU patients with COVID-19

Jan. 11, 2021

Positive phase IIb data presented for DBI-001 in tinea pedis

Jan. 11, 2021

Inhaled phage therapy YPT-01 enters phase I/II trial to treat P. aeruginosa in cystic fibrosis

Jan. 11, 2021

JMX-0207 inhibits Zika virus both in vitro and in vivo

Jan. 11, 2021

LY-CoV555 does not show efficacy in hospitalized patients with COVID-19

Jan. 8, 2021

GlaxoSmithKline plc discloses new antibacterials

Jan. 8, 2021

Phase III ultraVIOLET study of oteseconazole for recurrent VVC meets endpoints

Jan. 7, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...